EMA states blood clots register as a “very rare” side-effect of the AstraZeneca vaccine

The EU Medicines Agency (EMA) has said the benefits of the Oxford-AstraZeneca vaccination overcome any risks attached to it. The EMA stated it is recommending that blood clots may be a side-effect but are very rare.

The EMA’s Commission President, Sabine Strauss, said a thorough risk assessment on this vaccine has been carried out and she maintained the benefits of AstraZeneca far outweigh the risks and the risks are very rare.

Strauss noted that 53 cases of thrombosis have been reported among the 34 million persons that have been vaccinated with AstraZeneca.

She said the formation of blood clots is rare and for these incidents no specific reason have been established and that other specific risks have not been identified. Strauss added that further investigations are ongoing.

Her clarifications have paved the way for a continued programme using AstraZeneca without further delays throughout Europe. This follows many weeks of uncertainty.

In Malta the AstraZeneca vaccine is being administered to those aged 70 and under with Health Minister Chris Fearne stating that no cases of blood clots have been reported in the country.